Longeveron (LGVN) Stock Price, News & Analysis

Company Overview

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies. Its lead program targets aging frailty, a condition marked by decreased physical function and increased vulnerability in elderly populations. Additional trials are evaluating Lomecel-B in cognitive impairment, acute respiratory distress syndrome (ARDS), bronchopulmonary dysplasia (BPD) in preterm infants and inflammatory complications associated with viral infections. The company leverages collaborations with academic and clinical research centers across North America to advance its programs through Phase 1 and Phase 2 stages.

Headquartered in Miami, Florida, Longeveron conducts its preclinical and clinical operations primarily in the United States and Canada, with plans to expand into other regions as its regulatory strategy evolves. The company maintains partnerships with contract manufacturing organizations to support large-scale production and has engaged regulatory consultants to align its development programs with U.S. Food and Drug Administration guidelines. Longeveron’s approach emphasizes rigorous safety assessment and standardized quality controls to facilitate broader patient access upon potential approval.

Leadership at Longeveron includes Michael L. Bubb, President and Chief Executive Officer, who brings more than two decades of experience in biotechnology and regenerative medicine. Under his direction, the company has established its commercial strategy, overseen its initial public listing on NASDAQ and built a multidisciplinary team covering research, clinical development and regulatory affairs. Longeveron continues to explore strategic collaborations and licensing opportunities to advance its cell therapy platform toward commercial readiness.

Key Stats

• Today's Range: $0.85 to $0.90
• 50-Day Range: $0.48 to $1.16
• 52-Week Range: $0.48 to $1.80
• Volume: 206,671 shs
• Average Volume: 547,174 shs
• Market Capitalization: $19.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Hold

Longeveron Stock Analysis - MarketRank™

Longeveron scored higher than 47% of companies evaluated by MarketBeat, and ranked 511th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Longeveron has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Longeveron has a consensus price target of $5.50, representing about 545.7% upside from its current price of $0.85.

Amount of Analyst Coverage

Longeveron has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Longeveron are expected to grow in the coming year, from ($0.70) to ($0.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Longeveron is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Longeveron is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Longeveron has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.06% of the float of Longeveron has been sold short.

Short Interest Ratio / Days to Cover

Longeveron has a short interest ratio ("days to cover") of 2.71, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Longeveron has recently increased by 20.70%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Longeveron does not currently pay a dividend.

Dividend Growth

Longeveron does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.78

News Sentiment

Longeveron has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Longeveron this week, compared to 3 articles on an average week.

Search Interest

Only 6 people have searched for LGVN on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Longeveron insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.20% of the stock of Longeveron is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

10.01% of the stock of Longeveron is held by institutions.

LGVN Stock Analysis - Frequently Asked Questions

How have LGVN shares performed this year?

Longeveron's stock was trading at $0.5060 at the start of the year. Since then, LGVN stock has increased by 68.3% and is now trading at $0.8518.

How were Longeveron's earnings last quarter?

Longeveron Inc. (NASDAQ:LGVN) released its quarterly earnings data on Tuesday, March, 17th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.20. The firm earned $0.37 million during the quarter, compared to analysts' expectations of $0.11 million. Longeveron had a negative trailing twelve-month return on equity of 199.79% and a negative net margin of 1,893.58%.
Read the conference call transcript.

When did Longeveron's stock split?

Longeveron shares reverse split before market open on Wednesday, March 27th 2024.The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Longeveron IPO?

Longeveron (LGVN) raised $29 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 2,660,000 shares at $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. acted as the underwriters for the IPO.

How do I buy shares of Longeveron?

Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Longeveron own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Longeveron investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN).

Company Calendar

• Last Earnings: 3/17/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LGVN
• CIK: 1721484
• Web: www.longeveron.com
• Phone: 305-302-7158
• Fax: N/A
• Employees: 20
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Longeveron: $5.50
• High Price Target: $8.00
• Low Price Target: $3.00
• Potential Upside/Downside: +545.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.70 million
• Net Margins: -1,893.58%
• Pretax Margin: -1,893.58%
• Return on Equity: -199.79%
• Return on Assets: -143.21%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 1.33
• Quick Ratio: 1.33

Sales & Book Value

• Annual Sales: $1.20 million
• Price / Sales: 16.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.25 per share
• Price / Book: 3.41

Miscellaneous

• Outstanding Shares: 23,270,000
• Free Float: 20,662,000
• Market Cap: $19.82 million
• Optionable: Not Optionable
• Beta: -0.31